171 related articles for article (PubMed ID: 26653559)
1. In vitro and in vivo antileishmanial properties of a 2-n-propylquinoline hydroxypropyl β-cyclodextrin formulation and pharmacokinetics via intravenous route.
Balaraman K; Vieira NC; Moussa F; Vacus J; Cojean S; Pomel S; Bories C; Figadère B; Kesavan V; Loiseau PM
Biomed Pharmacother; 2015 Dec; 76():127-33. PubMed ID: 26653559
[TBL] [Abstract][Full Text] [Related]
2. Antileishmanial activity of a formulation of 2-n-propylquinoline by oral route in mice model.
Campos Vieira N; Vacus J; Fournet A; Baudouin R; Bories C; Séon-Méniel B; Figadère B; Loiseau PM
Parasite; 2011 Nov; 18(4):333-6. PubMed ID: 22091464
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo antileishmanial efficacy of a new nitrilquinoline against Leishmania donovani.
Nakayama H; Desrivot J; Bories C; Franck X; Figadère B; Hocquemiller R; Fournet A; Loiseau PM
Biomed Pharmacother; 2007; 61(2-3):186-8. PubMed ID: 17360145
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of 2-substituted quinolines as potential antileishmanial agents.
Gopinath VS; Pinjari J; Dere RT; Verma A; Vishwakarma P; Shivahare R; Moger M; Kumar Goud PS; Ramanathan V; Bose P; Rao MV; Gupta S; Puri SK; Launay D; Martin D
Eur J Med Chem; 2013 Nov; 69():527-36. PubMed ID: 24095747
[TBL] [Abstract][Full Text] [Related]
5. In Vitro susceptibilities of wild and drug resistant Leishmania donovani amastigotes to piperolactam A loaded hydroxypropyl-β-cyclodextrin nanoparticles.
Bhattacharya P; Mondal S; Basak S; Das P; Saha A; Bera T
Acta Trop; 2016 Jun; 158():97-106. PubMed ID: 26940000
[TBL] [Abstract][Full Text] [Related]
6. Development and evaluation of a cedrol-loaded nanostructured lipid carrier system for in vitro and in vivo susceptibilities of wild and drug resistant Leishmania donovani amastigotes.
Kar N; Chakraborty S; De AK; Ghosh S; Bera T
Eur J Pharm Sci; 2017 Jun; 104():196-211. PubMed ID: 28400285
[TBL] [Abstract][Full Text] [Related]
7. Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis.
Gupta S; Yardley V; Vishwakarma P; Shivahare R; Sharma B; Launay D; Martin D; Puri SK
J Antimicrob Chemother; 2015 Feb; 70(2):518-27. PubMed ID: 25389223
[TBL] [Abstract][Full Text] [Related]
8. Selection and phenotype characterisation of sitamaquine-resistant promastigotes of Leishmania donovani.
Bories C; Cojean S; Huteau F; Loiseau PM
Biomed Pharmacother; 2008 Mar; 62(3):164-7. PubMed ID: 18249083
[TBL] [Abstract][Full Text] [Related]
9. Co-administration of glycyrrhizic acid with the antileishmanial drug sodium antimony gluconate (SAG) cures SAG-resistant visceral leishmaniasis.
Bhattacharjee A; Majumder S; Majumdar SB; Choudhuri SK; Roy S; Majumdar S
Int J Antimicrob Agents; 2015 Mar; 45(3):268-77. PubMed ID: 25600891
[TBL] [Abstract][Full Text] [Related]
10. Novel arylimidamides for treatment of visceral leishmaniasis.
Wang MZ; Zhu X; Srivastava A; Liu Q; Sweat JM; Pandharkar T; Stephens CE; Riccio E; Parman T; Munde M; Mandal S; Madhubala R; Tidwell RR; Wilson WD; Boykin DW; Hall JE; Kyle DE; Werbovetz KA
Antimicrob Agents Chemother; 2010 Jun; 54(6):2507-16. PubMed ID: 20368397
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.
Seifert K; Pérez-Victoria FJ; Stettler M; Sánchez-Cañete MP; Castanys S; Gamarro F; Croft SL
Int J Antimicrob Agents; 2007 Sep; 30(3):229-35. PubMed ID: 17628445
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and visceral leishmaniases.
Nakayama H; Loiseau PM; Bories C; Torres de Ortiz S; Schinini A; Serna E; Rojas de Arias A; Fakhfakh MA; Franck X; Figadère B; Hocquemiller R; Fournet A
Antimicrob Agents Chemother; 2005 Dec; 49(12):4950-6. PubMed ID: 16304157
[TBL] [Abstract][Full Text] [Related]
13. Molecular docking, structure-activity relationship and biological evaluation of the anticancer drug monastrol as a pteridine reductase inhibitor in a clinical isolate of Leishmania donovani.
Kaur J; Sundar S; Singh N
J Antimicrob Chemother; 2010 Aug; 65(8):1742-8. PubMed ID: 20519355
[TBL] [Abstract][Full Text] [Related]
14. Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes.
Prajapati VK; Awasthi K; Gautam S; Yadav TP; Rai M; Srivastava ON; Sundar S
J Antimicrob Chemother; 2011 Apr; 66(4):874-9. PubMed ID: 21393222
[TBL] [Abstract][Full Text] [Related]
15. Nanotized Curcumin and Miltefosine, a Potential Combination for Treatment of Experimental Visceral Leishmaniasis.
Tiwari B; Pahuja R; Kumar P; Rath SK; Gupta KC; Goyal N
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031196
[TBL] [Abstract][Full Text] [Related]
16. In vivo and in vitro antileishmanial activity of Bungarus caeruleus snake venom through alteration of immunomodulatory activity.
Bhattacharya S; Ghosh P; De T; Gomes A; Gomes A; Dungdung SR
Exp Parasitol; 2013 Sep; 135(1):126-33. PubMed ID: 23830987
[TBL] [Abstract][Full Text] [Related]
17. Indolylquinoline derivatives are cytotoxic to Leishmania donovani promastigotes and amastigotes in vitro and are effective in treating murine visceral leishmaniasis.
Chakrabarti G; Basu A; Manna PP; Mahato SB; Mandal NB; Bandyopadhyay S
J Antimicrob Chemother; 1999 Mar; 43(3):359-66. PubMed ID: 10223591
[TBL] [Abstract][Full Text] [Related]
18. Asiaticoside induces tumour-necrosis-factor-α-mediated nitric oxide production to cure experimental visceral leishmaniasis caused by antimony-susceptible and -resistant Leishmania donovani strains.
Bhaumik SK; Paul J; Naskar K; Karmakar S; De T
J Antimicrob Chemother; 2012 Apr; 67(4):910-20. PubMed ID: 22258930
[TBL] [Abstract][Full Text] [Related]
19. CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis.
Sane SA; Shakya N; Haq W; Gupta S
J Antimicrob Chemother; 2010 Jul; 65(7):1448-54. PubMed ID: 20495208
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and pharmacological evaluation of mono-arylimidamides as antileishmanial agents.
Zhu X; Farahat AA; Mattamana M; Joice A; Pandharkar T; Holt E; Banerjee M; Gragg JL; Hu L; Kumar A; Yang S; Wang MZ; Boykin DW; Werbovetz KA
Bioorg Med Chem Lett; 2016 May; 26(10):2551-2556. PubMed ID: 27048943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
